RT Journal Article
SR Electronic
T1 Increased Plasma Caveolin-1 Levels Are Associated with Progression of Prostate Cancer among Japanese Men
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1893
OP 1897
VO 33
IS 5
A1 SATORU SUGIE
A1 SHOICHIRO MUKAI
A1 HIROMASA TSUKINO
A1 YOSHINOBU TODA
A1 TAKENORI YAMAUCHI
A1 ICHIRO NISHIKATA
A1 YOSHIKI KURODA
A1 KAZUHIRO MORISHITA
A1 TOSHIYUKI KAMOTO
YR 2013
UL http://ar.iiarjournals.org/content/33/5/1893.abstract
AB Aim: Up-regulation of caveolin-1 (CAV1) is associated with aggressive prostate cancer. Among Caucasian and African-American patients, plasma CAV1 levels are elevated in patients with castration-resistant prostate cancer (CRPC), but not in those with hormone-sensitive prostate cancer (non-CRPC), which implies that CAV1 could be a therapeutic target for CRPC. Here, we evaluated associations between plasma CAV1 levels and these types of cancer in Japanese men, and CAV1 expression in PC3 (CRPC) and LNCaP (non-CRPC) cell lines. Materials and Methods: Plasma samples were obtained from 58 patients with prostate cancer: 36 with CRPC and 22 with non-CRPC. Enzyme-linked immuno sorbent assay (ELISA) kits were used to determine CAV1 plasma levels; qRT-PCR and western blots were used to evaluate the expression of CAV1 mRNA and protein in cell lines. Results: Plasma CAV1 levels in patients with CRPC were greatly higher than in those with non-CRPC (1.46±1.37 ng/ml in CRPC; 0.56±0.32 ng/ml in non-CRPC, p<0.004). Western blot and real-time qRT-PCR showed CAV1 protein and mRNA in PC3 cells to be significantly overexpressed compared to its expression in LNCaP cells (p<0.0001). Conclusion: Our results showed a relationship between CAV1 expression and prostate cancer progression, and support the possibility of CAV1 as a therapeutic target for CRPC.